Aliza Asif

Aliza Asif

Auto-generated profile, based on publicly available information

Aliza Asif

King Edward Medical University Lahore Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2025 in Primary Care Diabetes
Verified
Journal Article
Closed access
MAMaheen Asif
Maheen Asif
AAAliza Asif
Aliza Asif
URUmmi Aiman Rahman
Ummi Aiman Rahman
HAHafsa Ajmal
Hafsa Ajmal
UJUzair Jafar
Uzair Jafar
OFOshaz Fatima
Oshaz Fatima

28 July 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
MAMaheen Asif
Maheen Asif
MNMudasar Nisar
Mudasar Nisar
AAAliza Asif
Aliza Asif
MBMakzooma Batool
Makzooma Batool
RIRabia Javed Iqbal
Rabia Javed Iqbal
MAMohammed Hammad Jaber Amin
Mohammed Hammad Jaber Amin
Background: Radioactive iodine (RAI) therapy is often administered post‐total thyroidectomy in patients with low‐risk differentiated thyroid carcinoma, despite guidelines advising against its routine application. Evidence regarding the efficacy of RAI in reducing recurrence and improving survival in low‐risk differentiated thyroid cancer (DTC) remains inconsistent. Methods: We conducted a systematic review and meta‐analysis of observational studies and randomized clinical trials that compare RAI versus no RAI in low‐risk DTC patients. Databases such as MEDLINE, Scopus, Cochrane Library, and Google Scholar were searched through December 2025. Outcomes included recurrence, recurrence‐free survival, treatment response, biochemical markers, and side effects. We performed statistical analysis using Review Manager (RevMan) 5.4 with a random‐effects model, reporting odds ratios (OR) with 95% confidence intervals, and significance set at p < 0.05. Heterogeneity was assessed using I 2 statistics. Results: Ten studies ( n = 5260) were included in the analysis. No statistically significant difference was observed between the two groups for recurrence (OR 0.66, 95% CI: 0.41–1.08; p = 0.10), 5‐year recurrence‐free survival (OR 2.47, 95% CI: 0.63–9.62; p = 0.19), or treatment response (excellent response: OR 1.00, 95% CI: 0.52–1.92; p = 1.00). Secondary outcomes, including serum thyroglobulin > 1 ng/mL (OR 1.20, 95% CI: 0.00–342.55; p = 0.95), elevated thyroglobulin antibodies (OR 0.91, 95% CI: 0.38–2.16; p = 0.83), xerostomia (OR 5.63, 95% CI: 0.05–667.24; p = 0.48), and dysphonia (OR 0.96, 95% CI: 0.53–1.72; p = 0.88), were also not significantly different between groups, although estimates were not precise. Conclusion: The available randomized and observational evidence does not demonstrate a clear, clinically meaningful benefit of routine RAI ablation in patients classified as low‐risk DTC. These findings should be interpreted with caution due to heterogeneity across studies, variability in outcome definitions, and the predominance of observational data.